Expertise in
7
conditions

Dr. Rashmi Chugh

Family Medicine
Dupage County Health Department
111 N County Farm Rd, 
Wheaton, IL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Dupage County Health Department
111 N County Farm Rd, 
Wheaton, IL 

Overview

Rashmi Chugh is a primary care provider, practicing in Family Medicine in Wheaton, Illinois.

Dr. Chugh is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor, and Fibrosarcoma.

She is actively involved in clinical research, co-authoring 110 peer reviewed articles and participating in 15 clinical trials.

Specialties

Family Medicine

Licenses

Family Medicine in IL

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

Dupage County Health Department
111 N County Farm Rd, Wheaton, IL 60187

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments
Enrollment Status: Active_not_recruiting
Publish Date: April 16, 2026
Intervention Type: Drug
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Letetresgene Autoleucel, Fludarabine, Cyclophosphamide
Study Phase: Phase 2
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: INBRX-109
Study Phase: Phase 2
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging
Enrollment Status: Completed
Publish Date: December 17, 2025
Intervention Type: Other, Drug, Diagnostic test
Study Drugs: Trabectedin, Irinotecan
Study Phase: Phase 1/Phase 2
Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Phase II Multi-Center Trial of Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Trabectedin
Study Phase: Phase 2
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Enrollment Status: Completed
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: April 09, 2025
Intervention Type: Drug
Study Drug: ASTX295
Study Phase: Phase 1
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Drug
Study Drugs: PLX3397, Sirolimus
Study Phase: Phase 1/Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
View 9 Less Clinical Trials

110 Total Publications

Investigating vimseltinib in tenosynovial giant cell tumors.
Investigating vimseltinib in tenosynovial giant cell tumors.
Journal: Expert opinion on pharmacotherapy
Published: January 25, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Craig Anderson
Family Medicine
Expertise in
9
conditions
Dr. Craig Anderson
Family Medicine

Office

801 N Cass Ave Ste 300, 
Westmont, IL 
 (9.3 miles away)
630-527-1818
Languages Spoken:
English
See accepted insurances

Craig Anderson is a primary care provider, practicing in Family Medicine in Westmont, Illinois. Dr. Anderson is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Stroke, Hypertension, Transient Ischemic Attack (TIA), Low Blood Pressure, and Thrombectomy.

Expertise in
109
conditions
Dr. Kamran Ayub
Family Medicine
Expertise in
109
conditions
Dr. Kamran Ayub
Family Medicine

GI Partners Of Illinois, LLC

9921 Southwest Hwy, 
Oak Lawn, IL 
 (21.6 miles away)
708-499-5678
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kamran Ayub is a Family Medicine provider practicing medicine in Oak Lawn, Illinois. Dr. Ayub is highly rated in 109 conditions, according to our data. His clinical expertise encompasses Bile Duct Obstruction, Gallstones, Watermelon Stomach, Endoscopy, and Gastrectomy. Dr. Ayub is board certified in American Board Of Internal Medicine, Gastroenterology.

Expertise in
19
conditions
Dr. Amit Garg
Family Medicine
Expertise in
19
conditions
Dr. Amit Garg
Family Medicine

Office

6195 W 115th St Ste A, 
Alsip, IL 
 (22.9 miles away)
312-262-7002
Languages Spoken:
English
See accepted insurances

Amit Garg is a primary care provider, practicing in Family Medicine in Alsip, Illinois. Dr. Garg is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Chronic Kidney Disease, Hidradenitis Suppurativa, High Potassium Level, Kidney Transplant, and Nephrectomy.

Frequently Asked Questions about Dr. Rashmi Chugh

How do I make an appointment with Dr. Rashmi Chugh?

You can book an appointment with Dr. Rashmi Chugh by calling their office at 630-682-7979. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Rashmi Chugh a top-rated expert for Osteosarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Rashmi Chugh is classified as an Distinguished expert for Osteosarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Rashmi Chugh specialize in?

While Dr. Rashmi Chugh is a Family Medicine, they have specific expertise in Osteosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Family Medicine.

Does Dr. Rashmi Chugh participate in research or clinical trials?

Yes. Dr. Rashmi Chugh has published 110 articles and abstracts on conditions like Osteosarcoma. You can view a list of Dr. Rashmi Chugh's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Rashmi Chugh accept my insurance?

Dr. Rashmi Chugh accepts most major insurance plans, including Cigna. We recommend calling the office directly at 630-682-7979 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chugh's expertise for a condition
ConditionClose
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile